Coxibs, selective inhibitors of cyclooxygenase-2 (COX-2), were developed to replace “traditional” non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis and acute pain. The gene discussed is PTGS2; the disease is arthritic joint disease.